CGB7: A Potential Drug Target for Pregnancy-Related Conditions

Target Name: CGB7

NCBI ID: G94027

CGB7

CGB7: A Potential Drug Target for Pregnancy-Related Conditions

CGB7, also known as chorionic gonadotropin beta subunit 7, is a protein that is expressed in the placenta and is known for its role in the development and maintenance of pregnancy. CGB7 has been identified as a potential drug target and a biomarker for various pregnancy-related conditions, including preterm birth, low birth weight, and postpartum depression.

CGB7 is a member of the Gonadotropin Receptor (GPR) family, which includes proteins that are involved in the signaling of gonadotropin ( GnRH ) in the brain. GnRH is a hormone that is produced by the pituitary gland and plays a crucial role in the development and maintenance of pregnancy.

CGB7 is expressed in the placenta, which is the tissue that provides nutrients and oxygen to the developing fetus. During pregnancy, the placenta is also responsible for producing CGB7, which is then released into the bloodstream. CGB7 has been shown to play a role in the development and maintenance of pregnancy, as well as the regulation of fetal growth and development.

One of the key functions of CGB7 is its role in the regulation of fetal brain development. CGB7 has been shown to promote the migration of neurons in the developing brain and to regulate the formation of neural connections. This is important for the development of the fetal brain and for the development of a healthy fetus.

CGB7 has also been shown to play a role in the regulation of fetal growth and development. CGB7 has been shown to promote the growth of the placenta and to regulate the production of growth factors in the placenta. This is important for the growth and development of the fetus, and for the production of a healthy fetus.

In addition to its role in the regulation of fetal brain development and growth, CGB7 has also been shown to play a role in the regulation of postpartum depression. CGB7 has been shown to be involved in the development of postpartum depression and has been shown to play a role in the regulation of symptoms of postpartum depression.

CGB7 has also been identified as a potential drug target for the treatment of various pregnancy-related conditions, including preterm birth, low birth weight, and postpartum depression. By targeting CGB7 with drugs, researchers hope to be able to improve outcomes for pregnant women and their babies.

Overall, CGB7 is a protein that is expressed in the placenta and is known for its role in the development and maintenance of pregnancy. CGB7 has been identified as a potential drug target and a biomarker for various pregnancy-related conditions, including preterm birth, low birth weight, and postpartum depression. Further research is needed to fully understand the role of CGB7 in pregnancy and to develop effective treatments for these conditions.

Protein Name: Chorionic Gonadotropin Subunit Beta 7

Functions: Beta subunit of the human chorionic gonadotropin (hCG). hCG is a complex glycoprotein composed of two glycosylated subunits alpha and beta which are non-covalently associated. The alpha subunit is identical to those in the pituitary gonadotropin hormones (LH, FSH and TSH). The beta subunits are distinct in each of the hormones and confer receptor and biological specificity. Has an essential role for pregnancy and maternal adaptation. Stimulates the ovaries to synthesize the steroids that are essential for the maintenance of pregnancy

The "CGB7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CGB7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets